title: The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.
authors: Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.
authors: S L
authors: SL
authors: Locatelli
authors: Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.
authors: G
authors: G
authors: Careddu
authors: Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.|Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.|Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA.
authors: G
authors: G
authors: Inghirami
authors: Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.
authors: L
authors: L
authors: Castagna
authors: TG Therapeutics, Inc., New York, NY, USA.
authors: P
authors: P
authors: Sportelli
authors: Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.|Humanitas University, Rozzano, Italy.
authors: A
authors: A
authors: Santoro
authors: Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.|Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy.
authors: C
authors: 0000-0003-3144-0124
authors: C
authors: Carlo-Stella
mesh_terms: D000079963:Brentuximab Vedotin; D016923:Cell Death / Q000187:drug effects*; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use*; D008938:Mitosis / Q000187:drug effects*; D000081082:Phosphoinositide-3 Kinase Inhibitors
chemical_list: D004791:Enzyme Inhibitors; D006576:Heterocyclic Compounds, 4 or More Rings; D018796:Immunoconjugates; D000081082:Phosphoinositide-3 Kinase Inhibitors; C000626319:umbralisib; D000079963:Brentuximab Vedotin